Clinical Trial: A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression

U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07446049) titled 'A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression' on June 26, 2025.

Brief Summary: This is a single-arm, open-label, multicenter, Phase Ib/II clinical trial of CVL237 tablets in combination with serplulimab injection for the treatment of advanced solid tumors with PTEN loss or low expression

Study Start Date: May 01

Study Type: INTERVENTIONAL

Condition: Locally Advanced or Metastatic Solid Tumors PTEN Loss or Low Expression

Intervention: DRUG: CVL237 tablets

CVL237 tablets, 2...